10421 Pacific Center Court
About AnaptysBio, Inc.
AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.
Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, our proprietary anti-interleukin-33 antibody, for the treatment of atopic dermatitis, eosinophilic asthma and chronic rhinosinusitis with nasal polyps.
In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).
Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.
Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.
Stock Exchange: NASDAQ
Stock Symbol: ANAB
92 articles with AnaptysBio, Inc.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB
Pomerantz LLP is investigating claims on behalf of investors AnaptysBio, Inc.
AnaptysBio Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Pipeline Updates
AnaptysBio today reported operating results for the fourth quarter and year ended December 31, 2019 and provided pipeline updates.
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the Cowen and Company 40th Annual Health Care Conference on Tuesday, March 3, 2020
J.P. Morgan 38th Annual Healthcare Conference on Wednesday, Jan. 15, 2020 at 2:30 p.m. PT at the Westin St. Francis in San Francisco.
The seven featured companies are the top companies headquartered in Biotech Beach based on 2018 revenue.
AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced topline data from its ATLAS trial, a Phase 2b randomized, double-blinded, placebo-controlled, multi-dose study in approximately 300 adult patients treated with etokimab in moderate-to-severe atopic dermatitis.
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating results for the third quarter ended September 30, 2019 and provided pipeline updates.
Peanut allergy is the most common food allergy in children and that number has been rising – peanut allergy incidence increased 21 percent from 2010 to 2017. Almost 2.5 percent of children in the US are thought to have a peanut allergy, according to the American College of Allergy, Asthma, and Im...
Shares of AnaptysBio were climbing this morning after the company released positive interim data for its experimental peanut allergy treatment. The San Diego-based company said 13 patients or 46 percent of those in its ongoing Phase IIa trial saw increased tolerance to peanuts to 500 mg.
12/29/2017A look at a few biotechs which should outperform the market in 2018.
12/21/2017A new RBC report is reasonably positive on the biotech sector for 2018 and here are some reasons why.
12/21/2017Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs.
Barring a huge meltdown, the S&P 500 will once again have a double-digit year of gains, and most investors should be looking at their 401(k)s and other accounts with some added holiday cheer.
Top-line data demonstrated favorable safety, pharmacokinetics and pharmacodynamic properties that support advancement of ANB019 into patient Phase 2 studies.
Cash, cash equivalents and investments totaled $116.7 million as of September 30, 2017, which includes net proceeds of $80.2 million from the company’s initial public offering completed in January 2017, compared to $51.2 million as of December 31, 2016.
AnaptysBio Reports Positive Topline Proof-Of-Concept Data From Phase IIa Clinical Trial Of ANB020 In Atopic Dermatitis